Fresenius Medical Care AG & Co. KGaA successfully amends and extends its credit agreement, ahead of schedule
Fresenius Medical Care successfully amends and extends its credit agreement, ahead of schedule
Fresenius Medical Care, the world's largest provider of dialysis products and services, has successfully refinanced its existing senior secured credit agreement, originally maturing in 2019.
The amended credit agreement now reflects a simplified, unsecured structure consistent with the investment grade rating of the company and lower tiered pricing. The new structure should also enable future bond issuances to be ranked pari passu with the credit agreement.
The new facility has an aggregate amount of approximately USD 3.9 billion and consists of revolving facilities and term loans, both U.S. Dollar and Euro denominated with maturities in 2020 and 2022.
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,654 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 310,473 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company's website at www.freseniusmedicalcare.com.
Disclaimer This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
12.07.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English
Company: Fresenius Medical Care AG & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg
Germany Phone: +49 (0) 6172- 609 2525 Fax: +49 (0) 6172- 609 2301 E-mail: email@example.com Internet: www.freseniusmedicalcare.com ISIN: DE0005785802, , WKN: 578580, 578583 Indices: DAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE End of News DGAP News Service